Division of Novartis AG
Latest From AveXis Inc.
Company’s promise to be more forthright, along with quality culture and policy upgrades, may have helped sway agency.
Zolgensma should receive a conditional approval, says the European Medicines Agency’s drug evaluation committee, the CHMP.
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
If Zolgensma gets the thumbs up from the EMA this week, it will likely get formal EU approval within a couple of months.
- Gene Therapy, Cell Therapy
- Large Molecule
- Drug Delivery
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Novartis AG
- Senior Management
David Lennon, PhD, Pres.
Brian K Kaspar, PhD, CSO
Andrew Knudten, SVP, Tech. Operations & CTO
Rick Modi, SVP, CBO
James J L’Italien, PhD, SVP, Chief Reg. & Quality Officer
- Contact Info
Phone: (847) 572-8280
2275 Half Day Rd.
Bannockburn, IL 60015
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.